These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 37196643)

  • 1. CAR NK-92 cell-mediated depletion of residual TCR+ cells for ultrapure allogeneic TCR-deleted CAR T-cell products.
    Kath J; Du W; Martini S; Elsallab M; Franke C; Hartmann L; Drosdek V; Glaser V; Stein M; Schmueck-Henneresse M; Reinke P; Volk HD; Abou-El-Enein M; Wagner DL
    Blood Adv; 2023 Aug; 7(15):4124-4134. PubMed ID: 37196643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential alternatives to αβ-T cells to prevent graft-versus-host disease (GvHD) in allogeneic chimeric antigen receptor (CAR)-based cancer immunotherapy: A comprehensive review.
    Tang C; Zhang Y
    Pathol Res Pract; 2024 Oct; 262():155518. PubMed ID: 39146830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integration of a CD19 CAR into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells.
    MacLeod DT; Antony J; Martin AJ; Moser RJ; Hekele A; Wetzel KJ; Brown AE; Triggiano MA; Hux JA; Pham CD; Bartsevich VV; Turner CA; Lape J; Kirkland S; Beard CW; Smith J; Hirsch ML; Nicholson MG; Jantz D; McCreedy B
    Mol Ther; 2017 Apr; 25(4):949-961. PubMed ID: 28237835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
    Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
    Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma.
    Harrer DC; Simon B; Fujii SI; Shimizu K; Uslu U; Schuler G; Gerer KF; Hoyer S; Dörrie J; Schaft N
    BMC Cancer; 2017 Aug; 17(1):551. PubMed ID: 28818060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A strategy to protect off-the-shelf cell therapy products using virus-specific T-cells engineered to eliminate alloreactive T-cells.
    Quach DH; Becerra-Dominguez L; Rouce RH; Rooney CM
    J Transl Med; 2019 Jul; 17(1):240. PubMed ID: 31340822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integration of ζ-deficient CARs into the
    Kath J; Franke C; Drosdek V; Du W; Glaser V; Fuster-Garcia C; Stein M; Zittel T; Schulenberg S; Porter CE; Andersch L; Künkele A; Alcaniz J; Hoffmann J; Abken H; Abou-El-Enein M; Pruß A; Suzuki M; Cathomen T; Stripecke R; Volk HD; Reinke P; Schmueck-Henneresse M; Wagner DL
    bioRxiv; 2023 Nov; ():. PubMed ID: 38116030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity.
    Ghosh A; Smith M; James SE; Davila ML; Velardi E; Argyropoulos KV; Gunset G; Perna F; Kreines FM; Levy ER; Lieberman S; Jay HV; Tuckett AZ; Zakrzewski JL; Tan L; Young LF; Takvorian K; Dudakov JA; Jenq RR; Hanash AM; Motta AC; Murphy GF; Liu C; Schietinger A; Sadelain M; van den Brink MR
    Nat Med; 2017 Feb; 23(2):242-249. PubMed ID: 28067900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR.
    Torikai H; Reik A; Liu PQ; Zhou Y; Zhang L; Maiti S; Huls H; Miller JC; Kebriaei P; Rabinovich B; Lee DA; Champlin RE; Bonini C; Naldini L; Rebar EJ; Gregory PD; Holmes MC; Cooper LJ
    Blood; 2012 Jun; 119(24):5697-705. PubMed ID: 22535661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TCR-NK Cells: A Novel Source for Adoptive Immunotherapy of Cancer.
    Karahan ZS; Aras M; Sütlü T
    Turk J Haematol; 2023 Feb; 40(1):1-10. PubMed ID: 36719099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HA-1H T-Cell Receptor Gene Transfer to Redirect Virus-Specific T Cells for Treatment of Hematological Malignancies After Allogeneic Stem Cell Transplantation: A Phase 1 Clinical Study.
    van Balen P; Jedema I; van Loenen MM; de Boer R; van Egmond HM; Hagedoorn RS; Hoogstaten C; Veld SAJ; Hageman L; van Liempt PAG; Zwaginga JJ; Meij P; Veelken H; Falkenburg JHF; Heemskerk MHM
    Front Immunol; 2020; 11():1804. PubMed ID: 32973756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia.
    Calviño C; Ceballos C; Alfonso A; Jauregui P; Calleja-Cervantes ME; San Martin-Uriz P; Rodriguez-Marquez P; Martin-Mallo A; Iglesias E; Abizanda G; Rodriguez-Diaz S; Martinez-Turrillas R; Illarramendi J; Viguria MC; Redondo M; Rifon J; Villar S; Lasarte JJ; Inoges S; Lopez-Diaz de Cerio A; Hernaez M; Prosper F; Rodriguez-Madoz JR
    Front Immunol; 2023; 14():1270843. PubMed ID: 37795087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategies for overcoming bottlenecks in allogeneic CAR-T cell therapy.
    Lv Z; Luo F; Chu Y
    Front Immunol; 2023; 14():1199145. PubMed ID: 37554322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of alphabeta- and gammadelta-T cells in allogenic donor marrow on engraftment, chimerism, and graft-versus-host disease.
    Huang Y; Cramer DE; Ray MB; Chilton PM; Que X; Ildstad ST
    Transplantation; 2001 Dec; 72(12):1907-14. PubMed ID: 11773887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T cell receptor gene-modified allogeneic T cells with siRNA for endogenous T cell receptor induce efficient tumor regression without graft-versus-host disease.
    Okada S; Muraoka D; Yasui K; Tawara I; Kawamura A; Okamoto S; Mineno J; Seo N; Shiku H; Eguchi S; Ikeda H
    Cancer Sci; 2023 Nov; 114(11):4172-4183. PubMed ID: 37675556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved Overall Survival, Relapse-Free-Survival, and Less Graft-vs.-Host-Disease in Patients With High Immune Reconstitution of TCR Gamma Delta Cells 2 Months After Allogeneic Stem Cell Transplantation.
    Minculescu L; Marquart HV; Ryder LP; Andersen NS; Schjoedt I; Friis LS; Kornblit BT; Petersen SL; Haastrup E; Fischer-Nielsen A; Reekie J; Sengelov H
    Front Immunol; 2019; 10():1997. PubMed ID: 31507601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Grade Manufacture of CYAD-101, a NKG2D-based, First in Class, Non-Gene-edited Allogeneic CAR T-Cell Therapy.
    Michaux A; Mauën S; Breman E; Dheur MS; Twyffels L; Saerens L; Jacques-Hespel C; Gauthy E; Agaugué S; Gilham DE; Sotiropoulou PA
    J Immunother; 2022 Apr; 45(3):150-161. PubMed ID: 35191428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in the T-cell receptor V beta gene repertoire after allogeneic hematopoietic stem cell transplantation.
    Liu QF; Li YQ; Yang D; Zhang Y; Yang LJ; Chen SH; Sun J; Liu XL; Zhou SY
    Chin Med J (Engl); 2004 Mar; 117(3):413-8. PubMed ID: 15043783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges and opportunities of allogeneic donor-derived CAR T cells.
    Yang Y; Jacoby E; Fry TJ
    Curr Opin Hematol; 2015 Nov; 22(6):509-515. PubMed ID: 26390167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
    Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
    Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.